Short Interest in Eisai Co., Ltd. (OTCMKTS:ESALY) Grows By 67.7%

Eisai Co., Ltd. (OTCMKTS:ESALYGet Rating) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 16,600 shares, an increase of 67.7% from the March 31st total of 9,900 shares. Based on an average daily trading volume, of 48,400 shares, the short-interest ratio is currently 0.3 days.

A number of research firms recently weighed in on ESALY. Zacks Investment Research lowered Eisai from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 12th. Citigroup downgraded Eisai from a “buy” rating to a “neutral” rating in a research note on Thursday, January 13th.

Shares of ESALY opened at $43.48 on Friday. The business’s fifty day simple moving average is $47.35 and its two-hundred day simple moving average is $55.91. The company has a current ratio of 1.92, a quick ratio of 1.62 and a debt-to-equity ratio of 0.07. Eisai has a 12 month low of $42.60 and a 12 month high of $129.79.

Eisai (OTCMKTS:ESALYGet Rating) last issued its earnings results on Thursday, February 3rd. The company reported $0.43 EPS for the quarter. Eisai had a return on equity of 7.62% and a net margin of 7.99%. The business had revenue of $1.79 billion for the quarter. Equities analysts expect that Eisai will post 1.8 earnings per share for the current year.

About Eisai (Get Rating)

Eisai Co, Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures.

Further Reading

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.